The regulation of the circadian rhythm is relayed from the central nervous system to the periphery by melatonin, a hormone synthesized at night in the pineal gland. Besides two melatonin G-coupled receptors, mt 1 and MT 2 , the existence of a novel putative melatonin receptor, MT 3 , was hypothesized from the observation of a binding site in both central and peripheral hamster tissues with an original binding profile and a very rapid kinetics of ligand exchange compared with mt 1 and MT 2 . In this report, we present the purification of MT 3 from Syrian hamster kidney and its identification as the hamster homologue of the human quinone reductase 2 (QR 2 , EC 1.6.99.2). Our purification strategy included the use of an affinity chromatography step which was crucial in purifying MT 3 to homogeneity. The protein was sequenced by tandem mass spectrometry and shown to align with 95% identity with human QR 2 . After transfection of CHO-K1 cells with the human QR 2 gene, not only did the QR 2 enzymatic activity appear, but also the melatonin-binding sites with MT 3 characteristics, both being below the limit of detection in the native cells. We further confronted inhibition data from MT 3 binding and QR 2 enzymatic activity obtained from samples of Syrian hamster kidney or QR 2 -overexpressing Chinese hamster ovary cells, and observed an overall good correlation of the data. In summary, our results provide the identification of the melatonin-binding site MT 3 as the quinone reductase QR 2 and open perspectives as to the function of this enzyme, known so far mainly for its detoxifying properties.
The regulation of the circadian rhythm is relayed from the central nervous system to the periphery by melatonin, a hormone synthesized at night in the pineal gland. Besides two melatonin G-coupled receptors, mt 1 and MT 2 , the existence of a novel putative melatonin receptor, MT 3 , was hypothesized from the observation of a binding site in both central and peripheral hamster tissues with an original binding profile and a very rapid kinetics of ligand exchange compared with mt 1 and MT 2 . In this report, we present the purification of MT 3 from Syrian hamster kidney and its identification as the hamster homologue of the human quinone reductase 2 (QR 2 , EC 1.6.99.2). Our purification strategy included the use of an affinity chromatography step which was crucial in purifying MT 3 to homogeneity. The protein was sequenced by tandem mass spectrometry and shown to align with 95% identity with human QR 2 . After transfection of CHO-K1 cells with the human QR 2 gene, not only did the QR 2 enzymatic activity appear, but also the melatonin-binding sites with MT 3 characteristics, both being below the limit of detection in the native cells. We further confronted inhibition data from MT 3 binding and QR 2 enzymatic activity obtained from samples of Syrian hamster kidney or QR 2 -overexpressing Chinese hamster ovary cells, and observed an overall good correlation of the data. In summary, our results provide the identification of the melatonin-binding site MT 3 as the quinone reductase QR 2 and open perspectives as to the function of this enzyme, known so far mainly for its detoxifying properties.
Melatonin, a neurohormone produced at night in the pineal gland, is suspected to relay to the peripheral organs the circadian rhythm detected by the central nervous system. Several high affinity melatonin receptors have been identified to date, among which the mt 1 (1) and MT 2 (2) receptors have been cloned from human tissues. The pharmacology of these two receptors is well documented, and several compounds, including melatonin, are ligands with picomolar binding affinity (for review, see Ref. 3) . Another putative melatonin receptor was identified on pharmacological grounds, with lower melatonin affinity (nanomolar range), very rapid ligand association/dissociation kinetics, and an original pharmacological profile (4 -6) . In line with mt 1 and MT 2 receptors, this putative receptor was named MT 3 , according to the nomenclature recommendations of the IUPHAR (7) . So far, the known inhibitors of MT 3 hardly reach the nanomolar range and encompass an unusually large structural diversity of highly hydrophobic cyclic or polycyclic compounds (Refs. 5 and 6, and for review, see Ref. 3) . 1 All pharmacological investigations on mt 1 , MT 2 , and MT 3 were performed using the radioligand [
125 I]melatonin, a ligand with high affinity for mt 1 and MT 2 (K d ϭ 10 -200 pM) and with lower affinity for MT 3 (K d ϭ 3-9 nM). The hamster kidney, liver, and brain have been used as model tissues for MT 3 pharmacological studies, and our recent data confirmed that among a wide range of mammals, this rodent was indeed the best source of MT 3 . 1 Hence, the binding specificity for [ 125 I]melatonin competition studies on MT 3 is achieved by preparing material from hamster tissues, and the fast dissociation kinetics is overcome by operating at 4°C. In addition, iodination of the known very specific MT 3 inhibitor, 5-methoxycarbonylamino-N-acetyltryptamine (MCA-NAT), 2 paved the way to more accurate and reliable investigations on MT 3 (5) . This ligand, combined with recently improved operating conditions, made possible for us to perform specific MT 3 pharmacological studies at room temperature. 1 Confident in the interest of discovering novel melatoninergic pharmacological targets, we recently set up a biochemical approach to identify and characterize MT 3 . The present report describes a specific purification procedure of MT 3 from hamster kidney, which led to a homogeneous single protein of 26 kDa, identified by tandem mass spectrometry as a homologue of the human quinone reductase 2 (QR 2 , EC 1.6.99.2). This identification was confirmed by confronting MT 3 pharmacological and QR 2 enzymatic data obtained under different cellular and biochemical conditions corresponding to MT 3 or QR 2 typical conditions. The quinone reductase family comprises two isoforms, QR 1 and QR 2 , which have been sequenced (8, 9) and crystallized (10, 11) . QR 2 lacks a 47-amino acid C-terminal sequence present in QR 1 , resulting in a differ-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ ‡ To whom correspondence should be addressed: Pharmacologie ent substrate specificity. It is noteworthy that the literature on QR 2 enzymology is rather scarce (12) (13) (14) . Interestingly, QR 2 was originally discovered in 1962 as a flavoenzyme (12) , later re-discovered as the QR 1 -related enzyme (14) , and was recently found again in porcine kidney as a puromycin aminonucleosidebinding protein (15) . We now unveiled a new facet of QR 2 as the melatonin-binding site MT 3, opening new perspectives in melatonin investigations as well as in quinone reduction studies.
EXPERIMENTAL PROCEDURES

Materials
[ 125 I]MCA-NAT (2200 Ci/mmol) was custom synthesized by Amersham Pharmacia Biotech (Orsay, France). 2-Iodomelatonin and MCA-NAT were purchased from Tocris (Bioblock, Illkirch, France), dihydrobenzylnicotinamide was obtained from Maybridge (Interchim, Montluçon, France), and all other reagents were obtained from SigmaAldrich (Saint Quentin Fallavier, France).
Partial Purification of MT 3
Frozen hamster kidneys were obtained from Charles River Breeding Laboratories (Saint Aubin les Elbeuf, France). The tissues were thawed, chopped, and added to 5 ml/g of homogenization buffer (50 mM Tris-HCl, pH 7.5, 0.2 M sucrose, 1 mM CaCl 2 , and Complete TM mixture of protease inhibitors). The cells were gently disrupted using a Dounce homogenizer and unbroken material and nuclei were pelleted at 280 ϫ g. The pellet (P 1 ) was treated identically a second time and the two 280 ϫ g supernatants were pooled (S 1 ) and supplemented with 5 mM final ␤-octyl glucopyranoside (OG) prior to a 30-min incubation under agitation. Cytoplasm and loose membrane-associated material was recovered in the supernatant of a 100,000 ϫ g centrifugation (S OG ) and the pellet (P OG ) was conserved for analysis. The S OG fraction was dialyzed against 20 mM Tris-HCl, pH 7.5, 1 mM CaCl 2 and applied to a 6 ϫ 5-cm DEAE Bio-Gel A column (Bio-Rad) pre-equilibrated with the same buffer. The elution of proteins was triggered by a stepwise gradient of 0 -1 M NaCl in the application buffer and was monitored by absorbence at 280 nm. The fractions of interest were pooled and dialyzed against the application buffer, concentrated by laying the dialysis tubing onto 20,000 Da polyethylene glycol, and further dialyzed against the application buffer. All procedures were carried out at 4°C. Most often, the OG solubilization sample S OG was flash frozen in liquid nitrogen and stored until application on the ion-exchange phase. For binding studies, this partially purified MT 3 sample was dialyzed against 20 mM Tris-HCl, pH 7.5, 1 mM CaCl 2 in order to remove the sucrose which inhibited MCA-NAT binding. The final DEAE sample was frozen identically before further purification or analysis. Fig.  1 ) was prepared in three steps from agomelatine (S20098 (16)) and attached to the polymer resin over a spacer, in two further steps, as 3 Purification of hamster kidney MT 3 was monitored by 125 I-MCA-NAT binding, QR 2 enzymatic activity (menadione/BNAH in the presence of dicoumarol), and QR 1 activity (menadione/NADH). Briefly, the tissue homogenate in 0.2 M sucrose (H) was centrifuged at low speed to remove nuclei and unbroken cells (P 1 ), and the resulting supernatant was incubated in mild detersive conditions (5 mM OG, fraction S1 ϩ OG) in order to separate cytoplasm and loosely membrane-associated material (S OG ) from membranes (P OG ). The cytoplasm-enriched fraction was dialyzed and fractionated by DEAE ion-exchange chromatography. The MT 3 -enriched fractions were pooled and concentrated (DEAE) before final purification by affinity chromatography (affinity). Data are representative of three independent purifications performed with five hamster kidneys as starting material. The affinity eluates were used for activity assays and electrophoresis analysis. The protein content was estimated by densitometry of the electrophoregram in the presence of a bovine serum albumin quantity calibration. Binding data are expressed as fmol/mg (specific binding) or fmol (total binding) of bound ligand. Enzymatic data are expressed as nmol/min/mg (specific activity) or nmol/min (total activity). a These data are part of a previous report (Footnote 1).
Chemical Synthesis of a MT 3 Specific Affinity Phase
The ligand N-[2-(7-amino-1-naphthyl)ethyl]-acetamide (S27145,
follows. A solution of N-[2-(7-methoxy-1-naphthyl)ethyl
]acetamide (10 g, 41 mmol) in DCM (50 ml) was treated with BBr 3 (25 ml) at Ϫ15°C under nitrogen. The reaction mixture was kept at Ϫ15°C for 1 h, then poured on, hydrolyzed with 1 N NaHCO 3 and extracted with methylethylketone. The organic layer was dried over sodium sulfate and concentrated. The residue was taken up with DCM (100 ml) and the precipitate collected and dried to afford 8.77 g (93%) of N-[2-(7-hydroxy-1-naphthyl)ethyl]acetamide (compound 1). A solution 1 (8.7 g, 38 mmol) in DCM (400 ml) was treated with triethylamine (6.9 ml, 50 mmol) and N-phenyl-bistrifluoromethane sulfonimide (20 g, 53 mmol). The reaction mixture was refluxed for 12 h, then cooled, concentrated, taken up with diethyl ether, washed with 1 N NaHCO 3 , water, and then dried over magnesium sulfate. The crude product was purified on silica gel with DCM/ethyl acetate (95:5) to afford 11.5 g (84%) of N-[2-(7-trifluoromethylsulfoxy-1-naphthyl)ethyl]acetamide (compound 2). A mixture of 2 (4.0 g, 11 mmol) with benzophenonimine (7 g, 38 mmol), bis(diphenylphosphino-1-1Ј-binaphthalene (310 mg, 0.5 mmol), palladium acetate (70 mg, 0.3 mmol), and cesium carbonate (5 g, 15 mmol) in dimethoxyethane (160 ml) was refluxed under nitrogen for 12 h. The resulting reaction mixture was hydrolyzed with water and extracted with diethyl ether. The organic layer was washed with 10% citric acid and water, then dried over sodium sulfate and concentrated. The resulting crude product was dissolved in tetrahydrofuran (150 ml), treated with 1 N HCl (200 ml), and heated at 60°C for 1 h. The reaction was cooled, extracted with diethyl ether, and the aqueous phase was brought to pH 11 with NaOH, then extracted with DCM. The organic layer was dried over sodium sulfate, concentrated, and purified on silica gel in DCM/methanol (97:3) to afford 1.44 g of N- [2-(7- . After a 15-min reaction at room temperature, high performance liquid chromatography showed no remaining amine and one major new product. Ethyl acetate (100 ml) was then added and the solution washed 3 times with brine (3 ϫ 25 ml), 1 M HCl (3 ϫ 25 ml), 5% NaHCO 3 (3 ϫ 25 ml), and brine (3 ϫ 25 ml), dried over magnesium sulfate and evaporated under vacuum. The yield of {5-[7-(2-acetylamino-ethyl)-naphthalen-2-ylcarbamoyl]-pentyl}-carbamic acid tert-butyrate, compound 4 (1.4 g), was 95% and its high performance liquid chromatography purity was 99%. The Boc group was deprotected by treatment of 4 (1.40 g, 3.17 mmol) with trifluoroacetic acid (10 ml) in DCM (20 ml). After 15 min at room temperature, the solution was evaporated under vacuum and lyophilized in water/ acetonitrile (9:1). The trifluoroacetic acid salt was then attached to the Novasyn TG carboxy resin (Novabiochem, 0.25 mmol/g) (12 g) on a semiautomatic synthesizer with axial shaking, using HATU (1.21 g, 3.17 mmol) in the presence of diisopropylethylamine (2.05 ml, 11.88 mmol) in a mixture of 200 ml of DCM/DMF (1:1) as solvent. The reaction mixture was shaken for 64 h at room temperature. After filtration, the usual washings were performed: 3 ϫ with DMF and isopropyl alcohol, alternatively and 3 times with DCM. The resin was then capped by treatment with a large excess of glycine methyl ester hydrochloride (3.98 g, 31.7 mmol) using HATU (12.05 g, 31.7 mmol) in the presence of diisopropylethylamine (7.65 ml, 44.4 mmol) in 200 ml of a mixture of DCM/DMF (1:1). The same washings were performed after filtration. Estimation of the substitution level of the resin was carried out by microanalysis of the nitrogen percentage content: 0.11 mmol ligand/g of resin.
Complete Purification of MT 3 The partially purified MT 3 sample was subjected to affinity chromatography at 4°C. The phase was synthesized as described above and used in a batch procedure. It was washed three times with 20 mM Tris-HCl, pH 7.5, 1 mM CaCl 2 and mixed with the sample at a ratio of 50 g of protein/mg of phase. The incubation was performed for 15 min under gentle agitation after which the sedimentation of the resin was left to occur. The unbound material was removed by pipetting over the supernatant and the phase was washed twice with the equilibration buffer. The bound proteins were eluted by incubating the phase for 15 min in the equilibration buffer supplemented with 50 M MCA-NAT. The eluate was recovered by pipetting, dialyzed against water, and concentrated on polyethylene glycol as described above. The precipitate obtained in dry ice-cold acetone was dried under a flow of nitrogen and analyzed by Laemmli polyacrylamide gel electrophoresis (17) . The proteins were detected in the gel by Coomassie Blue.
Mass Spectrometry Analysis of Purified MT 3
The protein spot in the Laemmli electrophoresis performed after affinity chromatography was excised from the Coomassie Blue-stained gel and washed with 50% acetonitrile. Gel pieces were dried in a vacuum centrifuge and reswollen in 20 l of 25 mM NH 4 HCO 3 containing 0.5 g of trypsin (Promega, sequencing grade). After 4 h incubation at 37°C, the gel pieces were extracted with 5% formic acid and acetonitrile. The extracts were evaporated to dryness. The residues were dissolved in 0.1% formic acid and desalted using a Zip Tip (Millipore). Elution of the peptides was performed with 5-10 l of 50% acetonitrile, 0.1% formic acid solution. The peptide solution was introduced onto a glass capillary (Protana) for nanoelectrospray ionization. Tandem mass spectrometry experiments were carried out on a Q-TOF hybrid mass spectrometer (Micromass, Altrincham, United Kingdom) in order to obtain sequence information. MS/MS sequence information was used for data base searching using the programs MS-Edman located at the University of California San Francisco and BLAST located at the NCBI.
cDNA-derived Expression of hQR 2 in Hamster Ovary CHO Cells and Preparation of Samples
The QR 2 coding sequence was isolated by reverse transcriptasepolymease chain reaction from human liver mRNA (CLONTECH, Palo Alto, CA) using the 5Ј sense primer (5Ј-GAATTCTCCACCATGGCAG-GTAAGAAAGTACTCATGTC-3Ј, nucleotides 176 -202) and the 3Ј antisense primer (5Ј-GCGGCCGCTCATTATTGCCCGAAGTGCCAGTGG-GCTGTGC-3Ј, nucleotides 843-871) generated from the published sequence (Ref. 9; access number JO2888). Liver mRNA (200 ng) was reverse-transcribed with oligo(dT) [12] [13] [14] [15] [16] [17] [18] in accordance with the firststrand cDNA synthesis protocol from Amersham Pharmacia Biotech. Polymerase chain reactions were performed in 100 l containing 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl 2 , 0.2 mM dNTP, 2 l of the singlestranded cDNA preparation, 0.3 M of each primer, and 2 units of pfu native polymerase (Stratagene) with a 35 cycles program of 94°C for 1 min, 65°C for 2 min, and 72°C for 2 min and a final extension at 72°C for 8 min. The amplified cDNA was then subcloned in-frame into EcoRI and NotI site of the pcDNA3.1(ϩ) vector (Invitrogen, San Diego, CA). CHO-K1 cells maintained in Ham's F12 medium supplemented with 10% fetal calf serum, 2 mM glutamine, 500 IU/ml penicillin, and 500 g/ml streptomycin were transiently transfected by the pcDNA3.1(ϩ)-QR 2 plasmid using LipofectAMINE as described by the manufacturer (Life Technologies). Fourty-eight hours after the beginning of transfection, the adherent cells were washed by phosphatebuffered saline and harvested in 10 ml of homogenization buffer (see "Purification of MT 3 ," above) and transferred from flask to flask. The cell supension obtained was adjusted to 0.2 M sucrose and spun at 280 ϫ g. The resulting nuclei-free supernatant was assayed for protein and MT 3 /QR 2 content.
Assays
All assays were performed in triplicate and data presented herein are representative of two to six individual experiments.
Total Protein-The protein concentration was determined by the method of Lowry (18) using bovine serum albumin as a standard.
MT 3 Pharmacological Data-The MT 3 binding was performed according to our original procedure. Incubation was stopped by filtration through a 96-well filtration support disposed directly onto a Multiscreen filtering apparatus (Milllipore) connected to a vacuum pump, allowing rapid filtration after the samples were loaded using a 96-well pipetting device (Transtar, Costar). The filter-associated radioactivity was measured in a ␤-scintillation counter (TopCount NXT, Packard). Samples from CHO culture and from the purification of MT 3 up to the ion exchange chromatography step were analyzed on glass fiber filters (GF/B Unifilter, Packard), while elution from the ion-exchange resin was followed using polyvinylidene difluoride filters (Immobilon TM Multiscreen, Millipore) presoaked in methanol and rinsed three times by 200 l of binding buffer. Alternatively, samples from the final purification steps, affinity chromatography, and ion exchange chromatography as an internal reference, were assayed for MT 3 binding using 96-well format size-exclusion chromatography. Eighty l of dry Sephadex G-25 fine (APB) were distributed into 96-well format polyvinylidene difluoride filters (Durapore TM Multiscreen, Millipore) using a Multiscreen powder dispensing apparatus. The exclusion phase was hydrated with 250 l of 20 mM Tris-HCl, pH 8.5, and spun at 550 ϫ g for 1 min in a 96-well plate basket. The phase was further rinsed three times using 120 l of the same buffer, left to equilibrate at 4°C for 30 min, and spun before sample application. The samples were preincubated at 4°C during 30 min with 200 pM [ 125 I]MCA-NAT as described above, and 120 l of the mixture were loaded onto the exclusion phase. The plates were immediately spun at 550 ϫ g for 1 min. The free radioligand was excluded from the eluate by diffusion in the chromatographic medium, and 90 l of the eluate were used for scintillation counting. For competition studies, the data presented are affinity constants (K i ) calculated from specific binding values of logarithmic compound concentrations, according to the method of Cheng and Prusoff (19) .
QR Enzymatic Activity-The measurements of QR 1 and QR 2 quinone reductase activities were adapted from Jaiswal et al. (9) and Zhao et al. (14) . QR 1 activity was measured using 100 M menadione as substrate and 100 M NADH as co-substrate, while QR 2 activity was measured using 100 M menadione as substrate, 100 M dihydrobenzylnicotinamide (BNAH) as co-substrate, and 100 M dicoumarol as QR 1 inhibitor. In both cases, the activities were measured at 25°C in 200 l of 20 mM Tris-HCl, pH 7.5, 1 mM OG and the reactions were followed at 440 nm using the intrinsic fluorescence of the two co-substrates with excitation at 340 nm (PolarStar 96-well plate reader, BMG, Offenburg, Germany). Samples were diluted before use in the measurement buffer supplemented with 10% glycerol, in order to apply the desired amount of protein in 20 l. The instrument was calibrated using a range of co-substrate concentrations. The IC 50 values were calculated from inhibition curves using semi-logarithmic plots of the compound concentrations (8 points). 3 and QR 2 -This work primarily focused on the melatonin-binding site MT 3 , which was studied and purified using [ 125 I]MCA-NAT binding (5) as a specific assay, designated herein as the "MT 3 assay." Purification of MT 3 from hamster kidney provided "partially purified MT 3 " and "MT 3 purified to homogeneity." The cloning and expression of the human QR 2 gene in CHO provided an identified source of this enzyme, which was assayed using the well described oxidoreduction mechanism involving a quinone (electron acceptor) and a nicotinic derivative (electron donor). For assaying the QR 2 enzymatic activity, menadione was the substrate and a commercially available fluorescent NADH analogue, dihydrobenzylnicotinamide (BNAH, Powell et al. (20) ), was used for the first time as the co-substrate. Dicoumarol, a potent QR 1 inhibitor and poor QR 2 inhibitor (14) was added to the assay to ensure QR 2 specificity. Control assays of QR 1 activity were performed when necessary, using menadione as the substrate and NADH as the co-substrate, which provided good QR 1 specificity since NADH is a very poor co-substrate for QR 2 (14, 20) . 3 , Although, in the light of our results presented thereafter, MT 3 and QR 2 seem to designate a unique protein, for convenience in the present report, we alternatively refer to hamster MT 3 or MT 3 /QR 2 and human QR 2 , depending on the methodological approach involved.
RESULTS
Terminology and Assays of MT
Purification and Identification of MT 3 as QR 2 -The purification of the melatonin-binding site MT 3 was performed as described under "Experimental Procedures" and the intermediate fractions were assayed for [ 125 I]MCA-NAT binding and QR 2 enzymatic activity. QR 1 activity was also assayed in all samples as a control. We started the purification of the MT 3 melatonin-binding site by preparing a nuclei-free subcellular fraction, from which MT 3 was recovered with high yield in the supernatant of a 100,000 ϫ g centrifugation after mild detergent treatment (5 mM octylglucoside). Dialysis removed most of the detergent molecules thanks to the high critical micellar concentration of OG (CMC OG ϭ 25 mM (21)). The dialysate was applied to a DEAE anion exchanger, from which MT 3 was eluted by a discontinuous gradient of NaCl. The MT 3 containing fractions were pooled and dialyzed in order to remove the NaCl. Finally, we purified MT 3 to homogeneity using an original affinity phase developed on the basis of the most specific MT 3 ligand known to date, MCA-NAT. The synthetic ligand (S27145, Fig. 1 ) bears an amine function in position 7 of naphthylethylacetamide, which was substituted by a 6-aminohexanoyl moiety in order to mimic the carbonylamide function of MCA-NAT. The free amino group of the aminohexanoic spacer was used for the attachment to the affinity matrix, a polyethylene glycol-derivatized polystyrene resin. The use of a naphthyl ring eliminated the photosensitivity associated with the indole ring. The affinity chromatographic step was performed at 4°C in a batch procedure, and the proteins specifically adsorbed on the phase were eluted by 50 M MCA-NAT. The eluate was analyzed by SDS-polyacrylamide gel electrophoresis, where it appeared as a single band of 26 kDa (Fig. 2) . The band was recovered from the electrophoresis acrylamide gel as a trypsin digest and was analyzed by tandem mass spectrometry. The resulting five peptidic sequences were compared with protein data bases for alignment and showed 95% similarity with the human quinone reductase 2, QR 2 (Fig. 3) . Table I displays the yields of the successive purification steps as calculated from MT 3 binding and QR 2 enzymatic assay data. The [ 125 I]MCA-NAT binding data are in good agreement with the QR 2 enzymatic data, with a 2.5-3.5-fold enrichment of MT 3 / QR 2 in the OG supernatant, and a 12.5-13.5-fold enrichment after DEAE chromatography, while QR 1 was barely detectable in the ion exchange chromatography eluate. After the affinity chromatographic step, the purification of MT 3 , as evaluated by [ 125 I]MCA-NAT binding and QR 2 enzymatic assay, reached a 10,000-fold factor of enrichment, confirming the identity of MT 3 with QR 2 . Absorption and desorption of the protein preparation from the affinity medium gave a relatively low yield of recovery of MT 3 and QR 2 signals (about 20%), probably due to the rapid kinetics of ligand exchange of MT 3 . Indeed, the dissociation constant at room temperature is about 0.3 s Ϫ1 , 1 and performing the affinity chromatographic step at 4°C could not completely counterbalance the rapid dissociation kinetics.
Cloning, Overexpression, and Tissue Distribution of QR 2 -The human QR 2 gene was amplified from total RNA of human liver (9) and was used for the preparation of CHO cells transiently expressing QR 2 . Four clones were prepared and transfected in CHO cells. MT 3 binding as well as QR 2 enzymatic activity were assayed on a nuclei-free fraction obtained as described under "Experimental Procedures." Data in Fig. 4 show an average of 33-fold increase in [
125 I]MCA-NAT binding in CHO-QR 2 , and an average of 259-fold increase in QR 2 activity as compared with native CHO cells. Hence, the amplifica- Ligand Specificity for MT 3 and QR 2 Assays-Several series of compounds were tested for their potency to inhibit either [ 125 I]MCA-NAT binding (MT 3 assay) or menadione/BNAH oxidoreduction (QR 2 assay) on hamster kidney-purified MT 3 /QR 2 and on transfected human QR 2 (Table II) . The MT 3 ligands showed an affinity for hamster MT 3 /QR 2 in the nanomolar range. Iodomelatonin was the most potent ligand, but also bound very tightly to mt 1 and MT 2 . As expected, melatonin and other melatoninergic compounds displayed no or low affinity for MT 3 /QR 2 . The QR 2 co-substrate BNAH was a ligand as potent as MCA-NAT, while, surprisingly, menadione displayed only poor affinity for hamster MT 3 /QR 2 . Dicoumarol, known to poorly inhibit QR 2 (14) exhibited poor affinity for MT 3 /QR 2 , while estradiol, which diminishes quinone reductase activity in Syrian hamster kidney (22) , had an intermediate affinity (about 600 nM).
The pattern of inhibition of [ 125 I]MCA-NAT binding described above for hamster MT 3 /QR 2 was conserved when the same assay was applied to a human QR 2 preparation. Nonetheless, the compounds exhibited a 2-20-fold lower affinity for human QR 2 compared with hamster MT 3 /QR 2 . This hamster/ human difference was also observed with the enzymatic data, where IC 50 were 1.5-20-fold higher with human QR 2 compared with hamster MT 3 /QR 2 . Besides, hamster MT 3 /QR 2 and human QR 2 had a similar Michaelis affinity for menadione and BNAH, with a K m of about 60 M for BNAH, comparable with the K m of NAD(P)H for QR 1 (20, 23) . Dicoumarol was confirmed as a poor inhibitor of QR 2 , with an IC 50 of about 600 M. Interestingly, the MT 3 compounds proved to be relatively good inhibitors of the enzyme, especially of the hamster preparation where the IC 50 of iodomelatonin and S26553 were in the micromolar range, well below the K m of the substrates. On the contrary, and similarly to the binding data, the mt 1 /MT 2 ligands did not inhibit the QR 2 enzymatic activity.
DISCUSSION
The first in-depth biochemical investigation of MT 3 , which was previously known solely on the basis of its peculiar melatoninergic pharmacological profile, and was often compared with the two well described mt 1 and MT 2 melatonin membrane receptors (4 -7, 24 ) is reported here. The MT 3 melatonin-binding site was purified to homogeneity using classical biochemical tools, and was identified by partial peptide sequencing as the homologue of the human quinone reductase 2, with 57 out of 71 amino acid identity. Furthermore, several clues support the identification of MT 3 as the hamster homologue of QR 2 . First, MT 3 has always exhibited enzyme-like kinetics of association/dissociation of its ligands (5, 6) , which has long been a hint to its pharmacological characterization with classical techniques. The identification of MT 3 as an enzyme therefore explains this point. Second, both MT 3 and QR 2 showed hydrophobic properties, while not behaving as genuine membrane proteins. Indeed, when hamster kidney membranes were prepared in the absence of detergent, MT 3 loosely associated with membrane components and fractionated almost equally in the pellet and in the supernatant of an ultracentrifugation. 3 This is consistent with the elution from the DEAE column at low ionic strength (30 -40 mM NaCl), and with the previously described hydrophobic properties of QR 2 (9, 14, 20, 25) . Third, the present QR 2 transfected (1-4) CHO cells. The four clones were prepared as described under "Experimental Procedures," transfected in CHO-K1 cells and the cells were cultured for 2 days before harvesting. The cells were gently disrupted and the nuclei fraction was removed by a 280 ϫ g centrifugation. Specific assays were performed in triplicates on the resulting fraction.
purification shows a good correlation between the purification factors calculated from "MT 3 data," i.e. [
125 I]MCA-NAT binding, and from "QR 2 data," i.e. menadione enzymatic reduction. This observation is of particular interest regarding the last step of purification which led to a 10,000-fold enrichment of both [ 125 I]MCA-NAT binding and QR 2 activity. Fourth, the affinity step which purified QR 2 to homogeneity was designed on the basis of a typical MT 3 ligand, MCA-NAT, which had poor structural similarity with either QR 2 substrates or inhibitors known to date. Nevertheless, these observations clearly called for additional data showing the correlation between the presence of MT 3 and QR 2 signals. For this purpose, the human QR 2 gene was inserted in a vector and transfected in CHO cells, leading to the apparition of both MT 3 and QR 2 phenotypes, which were otherwise absent in native cells. In itself, this result definitively associated MT 3 and QR 2 signals, and led to the unambiguous identification of MT 3 as the hamster homologue of the human QR 2 .
Thereafter, it was of particular interest to compare the properties of MT 3 ligands (iodomelatonin, MCA-NAT, S26553, Nacetylserotonin, and melatonin), mt 1 -and MT 2 -specific melatoninergic ligands (luzindole, serotonin, and tryptamine), and QR-active compounds (menadione, BNAH, dicoumarol, and estradiol) toward hamster MT 3 /QR 2 and human QR 2 in order to build up relevant cross-comparisons. The [
125 I]MCA-NAT binding and the QR 2 enzymatic data were in good agreement altogether, and the compounds evaluated showed similar relative affinities for hamster MT 3 /QR 2 and human QR 2 . Nevertheless, it is noteworthy that there was a 2-20-fold higher affinity of the compounds for hamster MT 3 /QR 2 relative to human QR 2 , most probably due to interspecies difference in the protein sequence and properties, as was already reported for a rat to human QR 1 comparison (26) . Besides, the two QR 2 substrates, menadione and BNAH, displayed very contrasted affinities to hamster MT 3 /QR 2 and human QR 2 , the former being a poor competitive inhibitor of [ 125 I]MCA-NAT binding. These differences in binding affinities may reflect the difference of behavior of these two compounds toward the catalytic site of MT 3 /QR 2 . Indeed, we suggest that menadione has a low affinity for a reduced FADcontaining enzyme which seems to be present in binding experiments, while in contrast BNAH has a higher affinity for the protein bearing this intermediate catalytic site.
Furthermore, all the values for the inhibition of [ 125 I]MCA-NAT binding were in the nanomolar range, while those of menadione/BNAH oxidoreduction were in the micromolar range. As these parameters are not often compared, this difference of 3 orders of magnitude is surprising at first glance. However, when making such a comparison, one must bear in mind the dynamic ping-pong mechanism occurring at the active site, as opposed to the simple ligand exchange occurring in the binding experiments. For this reason, comparison of absolute affinity constants is not relevant, in contrast to correlation representations. Indeed, Fig. 5 shows a good correlation between the data discussed above, whether the comparison applies to the enzymatic (Fig. 5A, left panel) or binding (Fig. 5A , right panel) data from hamster MT 3 /QR 2 and human QR 2 , or conversely, when it applied to the binding and enzymatic data obtained on hamster MT 3 /QR 2 (Fig. 5B, left panel) or human QR 2 (Fig. 5B, right panel) preparations.
In conclusion, we have purified to homogeneity the hamster kidney melatonin-binding site MT 3 , which, after sequencing by mass spectrometry, was identified as the hamster homologue of the human quinone reductase 2 (EC 1.6.99.2). It was further demonstrated an overall good correlation between data collected from [
125 I]MCA-NAT binding (MT 3 specific assay) and from menadione/BNAH ϩ dicoumarol oxidoreduction (QR 2 specific assay) experiments. The purification scheme led to a 10,000-fold enrichment in both the MT 3 binding and the QR 2 activity, and we showed that QR 2 activity and MT 3 binding both appeared after QR 2 transfection in CHO cells. Furthermore, we found that inhibition data obtained with various compounds classically involved in MT 3 ing site to date. It is now suggested that hamster QR 2 has an inhibition specificity different enough from human QR 2 to have appeared until now as a distinct protein called MT 3 , being in fact only an inter-species homologue. Furthermore, hamster MT 3 /QR 2 and, to a lower extent, human QR 2 , show interesting binding affinities for melatonin and MT 3 -specific ligands. The oxidoreductive properties of the QR 2 open the way for a novel enzymatic investigation of the highly debated antioxidant properties of melatonin (for review, see Ref 27) . Hence, in addition to the G protein-coupled receptors of melatonin (mt 1 and MT 2 ) and the transferase arylalkylamine N-acetyltransferase which controls the limiting step of melatonin biosynthesis (28) , MT 3 /QR 2 appears as a fourth molecular target to explore the multiple facets of melatonin action.
